Document Type

Article

Publication Date

9-1-2011

Comments

This article has been peer reviewed. It was published in: The Journal of investigative dermatology.

Volume 131, Issue 9, September 2011, Pages 1817-20.

The published version is available at DOI: 10.1038/jid.2011.147.. Copyright © Nature

Abstract

The recent RAF inhibitor trial with PLX4032/RG7204 in late-stage mutant B-RAF melanoma patients has been lauded as a success story for personalized cancer therapy since short-term clinical responses were observed in the majority of patients. However, initial responses were followed by subsequent tumor re-growth, and a subset of patients showed intrinsic resistance. Bi-directional translational efforts are now essential to determine the mechanisms underlying acquired/secondary and intrinsic resistance to RAF inhibitors.

Share

COinS